Navigation Links
QRxPharma Announces Strategic Partnership with Actavis
Date:12/20/2011

SYDNEY and BEDMINSTER, N.J., Dec. 20, 2011 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today execution of a binding Letter of Intent (LOI) with Actavis Inc. for the formation of a strategic partnership to commercialise MoxDuo IR in the U.S. acute pain marketplace.

MoxDuo IR is a patented 3:2 ratio fixed dose combination of morphine and oxycodone.  Actavis Inc. is a subsidiary of Actavis Group, hf a privately held company based in Europe with 10,000 employees and annual global sales in excess of EUR 1.8 billion. Actavis Group is the world's fourth largest generic pharmaceutical company with a growing franchise in branded products. 

The launch of MoxDuo IR in the U.S. is projected to occur in 3Q CY2012, and pre-launch preparations will begin immediately. 

Strategic partnership highlights include:  

  1. Actavis will receive exclusive rights to commercialise and further develop MoxDuo IR for the U.S. market while assuming all costs for product launch as well as ongoing marketing and sales efforts in the U.S. 
  2. Commencing at MoxDuo IR launch, Actavis will pay QRxPharma royalties of 10% up to 30% depending on net sales thresholds, except for a period starting 3-6 months following launch where QRxPharma will receive a 50% royalty on US$150 million in cumulative sales.
  3. QRxPharma retains a co-promotion/profit-share right, whereby QRxPharma can create its own sales force and provide up to 25% of the effective selling effort to U.S .prescribers at any time following the first 12 months after product launch.
  4. QRxPharma retains full flexibility to market MoxDuo IR outside the U.S.
  5. The binding LOI has been secured by the payment of a non-refundable upfront signing fee of US$6 million to QRxPharma.

The parties expect to execute a more detailed agreement by 15 March 2012.

"We are delighted to an
'/>"/>

SOURCE QRxPharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. QRxPharma Completes NDA Submission for MoxDuo® IR
2. QRxPharma Announces NDA Filing for MoxDuo® IR
3. QRxPharma Limited Announces A$14 Million Placement Together With a Share Purchase Plan
4. QRxPharma Announces Interim Analysis of Final Pivotal Phase 3 Study for MoxDuo®IR
5. QRxPharma to Sponsor Symposium at 13th World Congress on Pain Meeting
6. Frost & Sullivan Recognizes QRxPharma for Innovative Pain Relief Product MoxDuo
7. QRxPharma Receives Positive Feedback from Scientific Advice Meetings in Europe on MoxDuo®IR Development and Registration
8. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
9. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
10. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
11. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... -- Hanger, Inc. (NYSE: HGR ) announced today ... for the quarter ended September 30, 2014, on Thursday, ... call to discuss these results is scheduled to begin ... Those wishing to participate should call 1-877-662-6095. A replay ... dialing 1-855-859-2056 and referencing Conference ID # 91880739. ...
(Date:10/17/2014)... , Oct. 17, 2014 UBM Medica US announces ... leading online community and information resource for neurologists and other ... and Alzheimer disease , with discussions of the latest ... 1 million Americans have Parkinson disease , more than the ... Lou Gehrig disease. Diagnosis can be difficult because ...
(Date:10/17/2014)... Oct. 17, 2014 Research and ... "Research and Development Prospect of China Dialysis Market, ... Based on the 2013 version, this update ... about dialysis industry and the relevant effect in ... dialysis industry segmentations. Moreover, it analyzes Chinese private-owned ...
Breaking Medicine Technology:Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3Research and Development Prospect of China Dialysis Market, 2014-2018 2Research and Development Prospect of China Dialysis Market, 2014-2018 3
... WAILEA, Hawaii and SUNNYVALE, Calif., June 27, ... from two open-label, multi-center Phase 2,clinical trials ... Injection, the company's lead product,candidate, in combination ... (docetaxel) as a second-line treatment,for patients with ...
... WIRE)--Jun 27, 2007 - Columbia,Laboratories, Inc. (NASDAQ: ... multi-dose pharmacokinetic study of,vaginally-administered lidocaine, which the ... This 42-subject study was designed to provide ... bioadhesive vaginal lidocaine,formulation at three dose strengths ...
Cached Medicine Technology:Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 2Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 3Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 4Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 5Columbia Laboratories Reports Positive Results from Multi-dose,Pharmacokinetic Study of Vaginally-administered Lidocaine 2Columbia Laboratories Reports Positive Results from Multi-dose,Pharmacokinetic Study of Vaginally-administered Lidocaine 3
(Date:10/20/2014)... Columbus, OH (PRWEB) October 20, 2014 National ... Ohio Chapter of the American Academy of Pediatrics (Ohio AAP, ... Administration (NHTSA) in encouraging parents of teen drivers to talk ... hit the road. , Motor vehicle crashes are the leading ... 2,055 teen drivers involved in fatal crashes, and 859 (42%) ...
(Date:10/20/2014)... It’s hard to imagine what it’s like to live without ... world, it’s a reality. And while new shoes are considered ... walk barefoot on rocky terrain or sewage-lined streets just to ... , Buckner International's Shoes for Orphan Souls ... to encourage support for Air1 and while also providing new ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Do you ... interventions? Here comes a wonderful app Metassessor for teachers, ... development company helped its client “Intervention Development LLC” ... The app is designed for iOS 4.3 or later ... This app is optimized for iPhone 5. It is ...
(Date:10/19/2014)... October 20, 2014 Recently, BambooIndustry.com, one ... unveiled its new range of bamboo deckings . ... these natural items; they are now available at deeply ... people, it is hard to overstate the significance of ... attention to online services. The company’s workers are striving ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 Having been working ... a good knowledge of customer needs. According to James, one ... covered with dazzling sequins, or with high-low skirts that add ... a huge demand. Recently, LunaDress has unveiled its new selection ... of fact, the company’s brand new items are available in ...
Breaking Medicine News(10 mins):Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2
... that the public will use performance data to choose their ... a paper published on bmj.com today, two experts ... choice is not at present a strong lever for change, ... improved to optimise its effect. Research conducted over the ...
... HealthDay Reporter , WEDNESDAY, Nov. 24 (HealthDay News) -- ... of heartburn drugs while they were pregnant did not ... a large Danish study finds. This class of ... as Prilosec (omeprazole), Prevacid (lansoprazole) and Nexium (esomeprazole). All ...
... 24 (HealthDay News) -- Excessive alcohol consumption -- a common ... injury and death, warns the American College of Emergency Physicians ... when they get together with family and friends. "Very ... suffer the loss of a loved one because of an ...
... , WEDNESDAY, Nov. 24 (HealthDay News) -- Parents ... if they,re traveling during the holiday season, an expert warns. ... you can,t plan for everything, being prepared will help keep ... Cahill, an associate professor of pediatrics at Loyola University Chicago ...
... WEDNESDAY, Nov. 24 (HealthDay News) -- A study conducted ... for blacks than it is for whites. In fact, ... one-fifth higher than it is for whites in that state. ... on Smoking and Health at the U.S. Centers for Disease ...
... Americans get ready to travel to holiday gatherings with family and ... them are reminded that there are some things you need to ... pack a copy of all vaccination records so that you can ... those records if you board your pet while going on an ...
Cached Medicine News:Health News:Experts question whether patients will use performance data to choose their care 2Health News:No Link Between Heartburn Drugs and Birth Defects: Study 2Health News:No Link Between Heartburn Drugs and Birth Defects: Study 3Health News:Holiday Drinking Can Kill, Experts Warn 2Health News:Preparation Can Help Kids With Nut Allergies Travel Safely 2Health News:Black Smokers May Face Higher Death Risk Than Whites: CDC 2
Claes Shielded Retinotomy Scissors, Vertical...
... DxSelect is intended for qualitatively detecting antibodies ... serum. The test is indicated for testing ... an aid in the presumptive laboratory diagnosis ... intended for self-testing, and this test is ...
... Indirect immunofluorescent antibody (IFA) test for ... IgG antibodies to St. Louis Encephalitis virus ... Equine Encephalitis virus (EEE), and California Encephalitis/La ... 8-well slides with fixed individual spots of ...
... immunofluorescent antibody (IFA) test ... semi-quantitation of human serum ... viral capsid antigen (VCA). ... 12-well slides, FITC IgG ...
Medicine Products: